Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Anticancer Res. 2013 Dec;33(12):5501-6.
Although laparoscopic radical nephroureterectomy is the standard treatment for localized upper urinary tract urothelial carcinoma, open radical nephroureterectomy has been reported to have a different rate of intravesical recurrence.
Intravesical recurrence-free, progression-free, and overall survival rates among patients undergoing open and laparoscopic radical nephroureterectomy from 2002 to 2013 were analyzed.
Although no single factor predicted intravesical recurrence-free survival, a past history of bladder cancer or grade 3 was related to poorer intravesical recurrence-free survival rate in patients treated with laparoscopic radical nephroureterectomy. Moreover, the novel proposed risk classification based on our data clearly showed better progression-free survival and overall survival, as well as intravesical recurrence-free survival, in patients treated with laparoscopic radical nephroureterectomy.
The findings reported here may help urologists predict oncological outcomes and to plan follow-up schedules after laparoscopic radical nephroureterectomy.
尽管腹腔镜根治性肾输尿管切除术是治疗局限性上尿路尿路上皮癌的标准治疗方法，但已有报道称开放性根治性肾输尿管切除术的膀胱内复发率不同。
分析了 2002 年至 2013 年间接受开放性和腹腔镜根治性肾输尿管切除术的患者的无膀胱内复发、无进展和总生存率。
尽管没有单一因素可以预测无膀胱内复发生存率，但膀胱癌病史或 3 级与接受腹腔镜根治性肾输尿管切除术的患者的无膀胱内复发生存率较差相关。此外，根据我们的数据提出的新的风险分类清楚地表明，接受腹腔镜根治性肾输尿管切除术的患者具有更好的无进展生存率、总生存率和无膀胱内复发生存率。
这里报告的结果可能有助于泌尿科医生预测肿瘤学结果，并为腹腔镜根治性肾输尿管切除术后的随访计划。
